MedPath
HSA Approval

WELIREG® FILM-COATED TABLET 40MG

SIN17233P

WELIREG® FILM-COATED TABLET 40MG

WELIREG® FILM-COATED TABLET 40MG

May 9, 2025

MSD PHARMA (SINGAPORE) PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantMSD PHARMA (SINGAPORE) PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

TABLET, FILM COATED

ORAL

Medical Information

L01XX74

Manufacturer Information

MSD PHARMA (SINGAPORE) PTE. LTD.

MSD International GmbH

Active Ingredients

Belzutifan

40.00mg

Belzutifan

Documents

Package Inserts

Welireg PI.pdf

Approved: May 9, 2025

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

WELIREG® FILM-COATED TABLET 40MG - HSA Approval | MedPath